Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orismilast for the treatment of mild to severe hidradenitis suppurativa; A phase 2, open-label, proof of concept trial comparing the response to an oral tablet formulation of orismilast in adult patients with mild, moderate, and severe hidradenitis suppurativa; A single-centre, prospective, single arm, investigator-initiated clinical trial with 16 weeks twice times daily oral treatment

Next Previous
Trial Profile

Orismilast for the treatment of mild to severe hidradenitis suppurativa; A phase 2, open-label, proof of concept trial comparing the response to an oral tablet formulation of orismilast in adult patients with mild, moderate, and severe hidradenitis suppurativa; A single-centre, prospective, single arm, investigator-initiated clinical trial with 16 weeks twice times daily oral treatment

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orismilast (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Proof of concept; Therapeutic Use
  • Acronyms OSIRIS

Most Recent Events

  • 04 Dec 2024 According to an UNION Therapeutics media release, recent data from this study will be presented by Dr. Kim Kjoller, CEO of UNION, at the 7th Annual Evercore ISI HealthCONx Conference taking place on December 3-5, 2024 at The Loews Coral Gables Hotel in Coral Gables, Florida.
  • 09 May 2024 Status changed from recruiting to completed as per results published in the Journal of the European Academy of Dermatology and Venereology.
  • 01 May 2024 Results examining tolerability, safety and efficacy of oral phosphodiesterase-4 (PDE4) inhibitior orismilast 10-40 mg twice daily (BID) in HS published in the Journal of the European Academy of Dermatology and Venereology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top